Tumor-agnostic circulating cell-free DNA biomarkers for longitudinal minimal residual disease monitoring in NSCLC

Chen Hsiung Yeh

Publications : 0
Followers : 0

dentification of cancer patients who are at ongoing risk of relapse remains of high priority to direct
effective adjuvant therapy. Plasma circulating cell-free DNA (cfDNA) analyses offer an
unprecedented approach to identify patients with minimal residual disease (MRD) earlier than
clinical or radiological evidence, detecting drug resistance, progression and relapse with relatively
high sensitivity and specificity. Here we used longitudinal surveillance to profile cfDNA mutational
landscape in NSCLC patients undergoing EGFR-TKI. We demonstrated how cutting-edge cfDNAbased
NGS and digital qPCR technologies are defining new subgroups of patients with MRD for
individually tailored treatment strategy much earlier, and provide new surrogate endpoints for
early registration of these therapies.

Like this book? You can publish your book online for free in a few minutes!

Create your own flipbook

View Text Version Likes : 0
Category : All Report

Follow
Upload
0
Embed
Share

Tumor-agnostic circulating cell-free DNA biomarkers for longitudinal minimal residual disease monitoring in NSCLC